Affinage

ELOVL5

Very long chain fatty acid elongase 5 · UniProt Q9NYP7

Length
299 aa
Mass
35.3 kDa
Annotated
2026-04-28
69 papers in source corpus 22 papers cited in narrative 24 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ELOVL5 is an endoplasmic reticulum-resident fatty acid elongase that catalyzes the condensation step in elongation of C18 and C20 polyunsaturated fatty acids—including gamma-linolenic acid, stearidonic acid, and eicosapentaenoic acid—to longer-chain PUFAs such as arachidonic acid, DHA, and cis-vaccenic acid, but cannot elongate C22 PUFAs owing to a tryptophan residue at the position equivalent to Cys-217 of ELOVL2 (PMID:18838740, PMID:23873268). The PUFA products of ELOVL5 feed back to suppress SREBP-1c-driven lipogenesis, activate PPARβ-dependent triglyceride catabolism via ATGL induction, and stimulate the mTORC2–Akt2–FoxO1 axis to restrain gluconeogenesis (PMID:18838740, PMID:23099444, PMID:24814977). Missense mutations (e.g., p.G230V) cause spinocerebellar ataxia type 38 (SCA38) not through loss of catalytic activity but via protein misfolding, Golgi mislocalization, proteasomal degradation, and ER-stress-mediated Purkinje cell toxicity, while complete Elovl5 loss alters synaptosomal PUFA composition and impairs synaptic vesicle replenishment and endocannabinoid-mediated plasticity in cerebellar circuits (PMID:25065913, PMID:37199746, PMID:40789653). In multiple cancer types, ELOVL5-dependent elongation sustains membrane phospholipid acyl-chain composition, supports mitochondrial function, and activates AKT–mTOR signaling to drive proliferation, survival, and metastasis (PMID:33547161, PMID:35670054, PMID:34439125).

Mechanistic history

Synthesis pass · year-by-year structured walk · 16 steps
  1. 2007 Medium

    Establishing that ELOVL5 expression is tissue- and hormone-regulated: ELOVL5 mRNA was detected specifically in the basal layer of androgen-dependent sebaceous glands, linking the elongase to specialized lipid production in a defined secretory cell type.

    Evidence In situ hybridization on goat head vs. rump skin and orchidectomized controls

    PMID:17827874

    Open questions at the time
    • No direct functional assay of ELOVL5 enzymatic activity in these cells
    • Relevance to human sebaceous biology not tested
  2. 2008 High

    The first loss-of-function model established ELOVL5 as the in vivo enzyme required for elongating C18:3 n-6 → C20:3 n-6 and C18:4 n-3 → C20:4 n-3, and revealed that the resulting arachidonic acid and DHA depletion derepresses SREBP-1c, causing hepatic steatosis—thereby placing ELOVL5 products as feedback regulators of lipogenic transcription.

    Evidence Elovl5 knockout mouse with hepatic microsomal assays and dietary AA/DHA rescue

    PMID:18838740

    Open questions at the time
    • Structural basis for substrate specificity unknown
    • Whether ELOVL5 is rate-limiting in all tissues not addressed
  3. 2012 High

    Beyond lipogenesis, ELOVL5 was linked to glucose metabolism: its product cis-vaccenic acid induces rictor expression, enhances mTORC2-dependent Akt2 S473 phosphorylation, and promotes FoxO1 phosphorylation to suppress gluconeogenesis, establishing a lipid-to-glucose regulatory circuit.

    Evidence Adenoviral Elovl5 overexpression in obese mice and HepG2 cells with rictor siRNA epistasis and phospho-specific Western blotting

    PMID:23099444

    Open questions at the time
    • Whether cis-vaccenic acid acts directly on rictor transcription or through an intermediate is unclear
    • Physiological relevance in lean animals not shown
  4. 2013 High

    The molecular determinant distinguishing ELOVL5 from ELOVL2 substrate range was identified: a tryptophan at the position equivalent to Cys-217 of ELOVL2 prevents ELOVL5 from elongating C22 PUFAs, providing the first structural-level insight into elongase substrate selectivity.

    Evidence Chimeric Elovl2/Elovl5 proteins and point mutagenesis in yeast heterologous expression

    PMID:23873268

    Open questions at the time
    • No crystal or cryo-EM structure of either elongase
    • Mechanism by which this residue excludes C22 substrates not resolved at atomic level
  5. 2014 High

    Two advances refined ELOVL5 biology: (1) ELOVL5 missense mutations were identified as the cause of SCA38 via linkage analysis and shown to mislocalize the protein from ER to Golgi, establishing a neurodegenerative disease mechanism; (2) ELOVL5-derived fatty acids were shown to activate PPARβ-dependent ATGL induction, adding triglyceride catabolism to ELOVL5's metabolic repertoire.

    Evidence Family-based linkage/sequencing with subcellular localization imaging (SCA38); adenoviral overexpression in obese mice with PPARβ agonist and siRNA epistasis (TG catabolism)

    PMID:24814977 PMID:25065913

    Open questions at the time
    • Whether SCA38 mutations impair enzymatic activity or act purely by proteotoxicity was unresolved at this point
    • PPARβ activation mechanism by cis-vaccenic acid not defined
  6. 2015 Medium

    Identification of two functional SREBP binding sites in the ELOVL5 gene confirmed that SREBP-1 directly activates ELOVL5 transcription, closing a negative-feedback loop in which ELOVL5 products suppress SREBP-1c and SREBP-1c induces ELOVL5.

    Evidence Promoter deletion and luciferase reporter assays plus EMSA for SRE motifs

    PMID:26321664

    Open questions at the time
    • ChIP-seq confirmation in endogenous chromatin not performed
    • Relative contribution of each SRE not quantified in vivo
  7. 2017 Medium

    Two studies expanded ELOVL5 regulation and disease modeling: miR-218-5p was validated as a direct post-transcriptional repressor of ELOVL5 linking estrogen signaling to PUFA synthesis, and Elovl5 knockout mice were shown to recapitulate SCA38 with progressive motor deficits, cerebellar atrophy, and reduced Purkinje cell dendritic arborization.

    Evidence Luciferase 3'UTR reporter assay and miRNA gain/loss-of-function in chicken hepatocytes (miR-218-5p); Elovl5 KO mice with behavioral and morphometric cerebellar analysis (SCA38 model)

    PMID:28665359 PMID:29163054

    Open questions at the time
    • Synaptic and electrophysiological consequences of Elovl5 loss not yet examined
    • Whether miR-218-5p regulates ELOVL5 in mammalian hepatocytes not shown
  8. 2018 Medium

    ELOVL5 was established as the dominant elongase for C18–C20 PUFA elongation in human T cells, with expression upregulated upon T-cell activation, extending its physiological relevance to adaptive immunity.

    Evidence siRNA knockdown in primary human T cells and Jurkat cells with exogenous PUFA incorporation assays

    PMID:30293059

    Open questions at the time
    • Functional consequences for T-cell effector function not tested
    • Whether other elongases compensate during prolonged activation unknown
  9. 2021 Medium

    Multiple cancer studies converged to establish ELOVL5 as a driver of oncogenic lipid metabolism: in prostate cancer it is an AR target gene whose product cis-vaccenic acid sustains mitochondrial function and suppresses ROS; in renal cell carcinoma ELOVL5 promotes AKT-mTOR-STAT3 signaling and invasion; and its elongation products enhance lipid-raft AKT-mTOR signaling to drive enzalutamide resistance in neuroendocrine prostate cancer.

    Evidence ChIP, siRNA/shRNA/CRISPR KO, xenografts, lipidomics, and cis-vaccenic acid/AA/EPA rescue across multiple cancer cell models

    PMID:33547161 PMID:34439125 PMID:35670054

    Open questions at the time
    • Whether ELOVL5 inhibition has therapeutic selectivity over normal tissues is untested
    • Direct lipid species mediating AKT activation not identified
    • Contribution of specific PUFA products vs. total elongation flux unclear
  10. 2021 Medium

    Regional mapping in the CNS revealed that Elovl5 is most highly expressed in cerebellar Purkinje cells and olfactory mitral cells, directly explaining the selective vulnerability of these neurons in SCA38.

    Evidence Elovl5-reporter mouse line with immunofluorescence across CNS regions and glial cultures

    PMID:33994961

    Open questions at the time
    • Functional consequence of Elovl5 in oligodendrocytes and microglia not explored
    • Whether regional expression differences translate to differing lipid profiles not shown
  11. 2022 Medium

    An unexpected tumor-suppressive role was demonstrated: ELOVL5 loss in breast cancer promotes EMT and metastasis through lipid droplet accumulation, Smad2 acetylation, and TGFβ receptor upregulation, contrasting with its oncogenic role in other cancers and revealing context-dependent functions.

    Evidence shRNA knockdown, lipid droplet imaging, TGFβR and DGAT inhibitor epistasis, murine metastasis models

    PMID:36056008

    Open questions at the time
    • Mechanism by which lipid droplet accumulation drives Smad2 acetylation not defined
    • Reconciliation of tumor-suppressive vs. oncogenic roles across cancer types lacking
  12. 2023 High

    The SCA38 pathomechanism was refined: the p.G230V mutant retains normal catalytic activity but is proteotoxic, undergoing Golgi mislocalization, accelerated proteasomal degradation, and augmented UPR activation that reduces neuronal viability; structural modeling implicated disruption of a conserved disulfide bond linking Loop 2 and Loop 6.

    Evidence Enzymatic activity assays in patient fibroblasts, proteasome inhibitor treatment, UPR reporter assays in cortical neurons, homology modeling

    PMID:37199746

    Open questions at the time
    • No experimental structure of ELOVL5 to validate the Loop 2–Loop 6 disulfide model
    • Whether other SCA38 mutations share the same proteotoxic mechanism untested
  13. 2023 Medium

    Elovl5 loss on an LDLR-deficient background activated SREBP-1, increased hepatic and plasma lipids, and caused atherosclerosis, demonstrating that ELOVL5 deficiency drives cardiovascular disease through the same SREBP-1 derepression mechanism identified in 2008.

    Evidence Elovl5−/−;Ldlr−/− double knockout mice with lipoprotein profiling and aortic plaque quantification

    PMID:38000296

    Open questions at the time
    • Contribution of macrophage-intrinsic vs. hepatic Elovl5 loss to atherosclerosis not dissected
    • Whether ELOVL5 products directly influence vascular wall lipid metabolism unknown
  14. 2024 Medium

    miR-218-5p was validated as a direct ELOVL5 repressor in mammalian hepatocytes, with epistasis (si-Elovl5 blocking miR-218-5p inhibitor effects) confirming ELOVL5 as the functional target mediating miR-218-5p's pro-lipogenic action via SREBP1 in NAFLD.

    Evidence Dual luciferase reporter, miR gain/loss-of-function with si-Elovl5 epistasis in AML12 cells and HFD mouse model

    PMID:38972428

    Open questions at the time
    • Whether miR-218-5p regulation of ELOVL5 is relevant beyond the liver not tested
    • Upstream signals controlling miR-218-5p in NAFLD not identified
  15. 2025 High

    Direct electrophysiological evidence linked ELOVL5-dependent synaptosomal lipid composition to synaptic function: Elovl5 loss impairs readily releasable pool replenishment at climbing fiber and parallel fiber synapses and shortens endocannabinoid-mediated suppression of excitation in Purkinje cells, providing a synaptic mechanism for SCA38 cerebellar dysfunction.

    Evidence Elovl5 KO mice with paired-pulse and high-frequency stimulation electrophysiology in Purkinje cells plus synaptosome lipidomics

    PMID:40789653

    Open questions at the time
    • Specific lipid species responsible for vesicle replenishment deficit not identified
    • Whether exogenous PUFA supplementation rescues synaptic phenotypes not tested
  16. 2025 Medium

    A novel non-enzymatic function was uncovered: ELOVL5 physically interacts with STING and prevents TBK1 recruitment and STING translocation to the Golgi, restraining innate inflammatory signaling and facilitating lung tissue repair after influenza infection.

    Evidence In vivo CRISPR screen, conditional KO in lung epithelial cells, ELOVL5–STING co-immunoprecipitation, STING–TBK1 interaction and Golgi trafficking assays (preprint)

    Open questions at the time
    • Preprint; not yet peer-reviewed
    • Whether STING binding depends on ELOVL5 enzymatic activity or is independent not determined
    • Reciprocal IP and domain mapping not reported

Open questions

Synthesis pass · forward-looking unresolved questions
  • Major unresolved questions include the atomic structure of ELOVL5, the identity of specific PUFA species mediating AKT-mTOR activation versus synaptic function, reconciliation of oncogenic versus tumor-suppressive roles across cancer types, and whether the STING-binding function is enzymatic-activity-independent.
  • No experimental structure (X-ray or cryo-EM) of any mammalian ELOVL family member
  • Specific lipid mediators linking ELOVL5 products to AKT phosphorylation unidentified
  • Therapeutic window for ELOVL5 modulation in cancer or neurodegeneration unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016740 transferase activity 4 GO:0098772 molecular function regulator activity 3
Localization
GO:0005783 endoplasmic reticulum 2 GO:0005794 Golgi apparatus 2
Pathway
R-HSA-1430728 Metabolism 5 R-HSA-162582 Signal Transduction 3 R-HSA-1643685 Disease 3 R-HSA-112316 Neuronal System 1
Partners
RICTORSREBF1STING

Evidence

Reading pass · 24 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2008 ELOVL5 is required in vivo for elongation of gamma-linolenic acid (C18:3 n-6) to dihomo-gamma-linolenic acid (C20:3 n-6) and stearidonic acid (C18:4 n-3) to omega3-arachidonic acid (C20:4 n-3); deletion of Elovl5 in mice reduces arachidonic acid and DHA levels, which activates SREBP-1c and its target genes, leading to hepatic steatosis reversible by dietary arachidonic acid and DHA supplementation. Elovl5 knockout mouse model, liver microsomal enzyme assay, dietary supplementation rescue Journal of lipid research High 18838740
2012 Elovl5 controls gluconeogenesis through the mTORC2-Akt2-FoxO1 pathway: elevated Elovl5 activity increases cis-vaccenic acid (18:1 n-7) synthesis, induces rictor mRNA and protein, promotes rictor-mTOR interaction, and selectively phosphorylates Akt2-S473 (mTORC2 site) but not Akt2-T308, leading to FoxO1-S256 phosphorylation and reduced nuclear FoxO1; rictor knockdown blocks these effects. Adenoviral overexpression of Elovl5 in obese mice and HepG2 cells, Akt inhibitor treatment, rictor siRNA knockdown, fatty acid analysis, phospho-specific Western blotting Journal of lipid research High 23099444
2014 Elovl5 activity regulates hepatic triglyceride catabolism in obese mice by producing fatty acid products (including cis-vaccenic acid) that activate PPARβ-dependent induction of ATGL (adipocyte triglyceride lipase) mRNA and protein, thereby promoting TG catabolism without affecting β-oxidation capacity; Elovl5 also reduces ER stress markers. Adenoviral Elovl5 overexpression in obese C57BL/6J mice, PPARβ agonist treatment, siRNA knockdown, fatty acyl carnitine profiling, Western blotting Journal of lipid research High 24814977
2013 The differential ability of rat Elovl5 vs Elovl2 to elongate C22 omega-3 docosapentaenoic acid (DPA, 22:5n-3) to 24:5n-3 is determined by a single residue: cysteine at position 217 in Elovl2 (critical for DPA elongation) vs tryptophan at the equivalent position in Elovl5 (which cannot elongate DPA); this was established by chimeric protein and point mutation analysis in a yeast expression system. Yeast heterologous expression, Elovl2/Elovl5 chimeras, site-directed mutagenesis, fatty acid profiling Journal of lipid research High 23873268
2014 ELOVL5 missense mutations (p.Gly230Val and p.Leu72Val) cause spinocerebellar ataxia type 38 (SCA38); mutant ELOVL5 shows aberrant perinuclear/Golgi accumulation rather than the normal widespread ER distribution, and affected individuals have reduced serum arachidonic acid and DHA. Linkage analysis, targeted resequencing, Sanger sequencing in families, transfection with subcellular localization imaging (immunofluorescence), serum fatty acid profiling American journal of human genetics High 25065913
2017 Elovl5 knockout mice develop progressive motor deficits (beam balance test), hyposmia, and cerebellar atrophy with reduced molecular layer thickness and decreased distal Purkinje cell dendritic arborization (by Sholl analysis of biocytin-filled PCs), recapitulating SCA38 symptoms; dendritic spine density is preserved. Elovl5 knockout mouse model, behavioral testing, morphometric cerebellar analysis, biocytin filling with Sholl dendritic analysis Frontiers in cellular neuroscience High 29163054
2021 ELOVL5 is directly transcriptionally induced by the androgen receptor (AR) in prostate cancer; ELOVL5 depletion alters mitochondrial morphology and function, increases reactive oxygen species, and suppresses prostate cancer cell proliferation, 3D growth, and in vivo tumor growth and metastasis; supplementation with cis-vaccenic acid (a direct ELOVL5 elongation product) reverses oxidative stress and proliferation/migration defects of ELOVL5 knockdown. Transcriptomics, ChIP, ELOVL5 siRNA/shRNA knockdown, mass spectrometry lipidomics, ROS assays, mitochondrial function assays, xenograft mouse models, cis-vaccenic acid supplementation rescue Cancer research High 33547161
2015 Two SREBP binding sites in the human ELOVL5 gene (one ~10 kb upstream, one in exon 1) are identified as functional enhancer elements conserved among mammals; SREBP activates ELOVL5 transcription through these SRE motifs, establishing ELOVL5 as a direct SREBP-1 target gene within a negative feedback loop of de novo lipogenesis. Promoter/enhancer deletion analysis, luciferase reporter assays, electrophoretic mobility shift assay (EMSA) Biochemical and biophysical research communications Medium 26321664
2021 ELOVL5-mediated fatty acid elongation in renal cell carcinoma promotes AKT Ser473 phosphorylation and AKT-mTOR-STAT3 signaling, supporting cell invasion via CCL2 upregulation; ELOVL5 knockout suppresses lipid droplet formation and induces apoptosis via ER stress; supplementation with arachidonic acid and EPA partially reverses proliferation and invasion defects. CRISPR/Cas9 ELOVL5 knockout, LC-MS lipidomics, Western blotting for AKT/mTOR/STAT3 signaling, fatty acid supplementation rescue, in vivo xenograft Cancer science Medium 35670054
2021 ELOVL5-mediated PUFA elongation enhances lipid raft-associated AKT-mTOR signaling, contributing to enzalutamide resistance in neuroendocrine-like prostate cancer cells; ELOVL5 knockdown reduces neuroendocrine phenotype and resistance, while overexpression augments resistance in vitro and in vivo. shRNA knockdown, ELOVL5 overexpression, enzalutamide resistance assays, lipid raft isolation, AKT-mTOR signaling Western blotting, xenograft models Cancers Medium 34439125
2022 Downregulation of ELOVL5 in breast cancer promotes EMT, cell invasion, and lung metastasis through lipid-droplet accumulation-dependent Smad2 acetylation, which upregulates TGF-β receptors; inhibition of TGF-β receptors or diacylglycerol acyltransferase (blocking lipid droplet formation) reverses invasion and metastasis caused by ELOVL5 loss. shRNA knockdown, lipid droplet imaging, TGF-β receptor inhibitor treatment, DGAT inhibitor treatment, Smad2 acetylation assay, murine breast cancer metastasis models Cell death & disease Medium 36056008
2023 The SCA38-causing ELOVL5 p.G230V variant has normal enzymatic activity but is proteotoxic: it is mislocalized to the Golgi (instead of ER), undergoes increased proteasomal degradation, triggers unfolded protein response more strongly than wild-type, and decreases neuronal viability; homology modelling reveals p.G230V shifts Loop 6 and alters a conserved disulfide bond connecting Loop 2 and Loop 6 that is elongase-specific. Biochemical elongase activity assay in SCA38 fibroblasts, proteasome inhibitor treatment, UPR reporter assays in cortical neurons, immunofluorescence localization, homology structural modelling Human genetics High 37199746
2018 ELOVL5 is the key elongase responsible for elongation of 18- and 20-carbon PUFAs in human T-cells; ELOVL5 expression is significantly upregulated upon T-cell activation/proliferation, and ELOVL5 knockdown markedly impairs elongation of these substrates and alters cellular PUFA profiles; no functional ELOVL2 was detected in these cells. siRNA knockdown of ELOVL5 in primary human T-cells and Jurkat cells, exogenous PUFA incorporation assays, RT-qPCR, fatty acid profiling Journal of lipid research Medium 30293059
2021 ELOVL5 knockdown in bovine embryos reduces the content of specific phospholipid species (phosphatidylcholines, phosphatidylethanolamines) and triacylglycerol, while increasing cytoplasmic lipid droplet deposition, demonstrating that ELOVL5 participates in embryonic lipid composition of cellular membranes. Morpholino-mediated knockdown in bovine embryos, mass spectrometry-based lipid fingerprinting, lipid droplet imaging International journal of molecular sciences Medium 33525659
2025 In Elovl5 knockout mouse cerebellum, deletion increases 18- and 20-carbon PUFAs, decreases long-chain PUFAs, and increases saturated/monounsaturated fatty acids in synaptosomes; loss of Elovl5 impairs replenishment of the readily releasable pool of synaptic vesicles at climbing fiber and parallel fiber synapses, and shortens endocannabinoid-mediated suppression of excitation (SSE) in Purkinje cells, linking ELOVL5-dependent lipid composition to synaptic transmission and plasticity. Elovl5 knockout mice, electrophysiological recordings in Purkinje cells (paired-pulse and high-frequency stimulation protocols), synaptosome lipid analysis, SSE assays The Journal of neuroscience High 40789653
2021 Elovl5 expression in the adult mouse CNS is region- and cell-type-specific: highest in cerebellar Purkinje cells, mitral cells of olfactory regions, brainstem, and motor-related telencephalic regions; Elovl5 is expressed in oligodendroglial cells at various maturation stages and in microglia, with heterogeneous expression in astrocytes. Elovl5-reporter mouse line, immunofluorescence on CNS sections, primary glial cell cultures Frontiers in neuroanatomy Medium 33994961
2007 ELOVL5 mRNA is specifically localized to the basal layer of sebaceous gland cells in the pheromone-producing head skin of male goats but absent in non-pheromone-producing rump skin and orchidectomized goat head skin, implicating ELOVL5 in pheromone fatty acid synthesis in sebaceous glands. In situ hybridization on goat skin sections The Journal of reproduction and development Medium 17827874
2017 Estrogen promotes hepatic LCPUFA synthesis by downregulating miR-218-5p, which directly targets and represses ELOVL5; miR-218-5p binds the 3'UTR of ELOVL5 (validated by luciferase reporter assay) and negatively regulates ELOVL5 mRNA and protein levels, thereby modulating PUFA biosynthesis at the post-transcriptional level. Luciferase 3'UTR reporter assay, miRNA mimic/inhibitor transfection, Western blotting, qPCR in chicken hepatocytes International journal of molecular sciences Medium 28665359
2019 miR-21-3p directly targets the 3'UTR of Elovl5 in bovine mammary epithelial cells (validated by luciferase reporter assay) and negatively regulates Elovl5 mRNA and protein; miR-21-3p mimics promote triglyceride production, an effect attributed to Elovl5 suppression. Luciferase 3'UTR reporter assay, miRNA mimic/inhibitor transfection, qPCR, Western blotting DNA and cell biology Medium 30707627
2024 miR-218-5p directly targets and suppresses Elovl5 expression in mouse hepatocytes (validated by dual luciferase reporter assay); miR-218-5p inhibition upregulates Elovl5 and suppresses SREBP1-mediated lipogenesis signaling, reducing lipid accumulation in a palmitic acid-induced NAFLD model; the pro-lipogenic effect of miR-218-5p is blocked by si-Elovl5, confirming Elovl5 as the functional target. Dual luciferase reporter assay, gain/loss-of-function miRNA experiments in AML12 cells and HFD mouse model, SREBP1 pathway Western blotting Biochemical pharmacology Medium 38972428
2023 Deletion of Elovl5 in LDLR-deficient mice activates SREBP-1, increases hepatic triglyceride and cholesterol, elevates VLDL/IDL/LDL plasma lipids, and results in marked aortic atherosclerotic plaques; Elovl5-deficient macrophages show slightly elevated PGE2 secretion (likely due to Cox-2) but no major differences in M1/M2 polarization markers. Elovl5-/-;Ldlr-/- double knockout mice, lipoprotein profiling, hepatic lipid analysis, aortic plaque quantification, bone marrow-derived macrophage polarization assays Biochemical and biophysical research communications Medium 38000296
2025 ELOVL5 physically binds to STING and inhibits TBK1 interaction with STING and its translocation to the Golgi, thereby reducing STING-mediated inflammatory signaling in lung epithelial cells; Elovl5 deficiency impairs lung inflammation resolution after influenza infection and reduces AKT1-mediated tissue repair; ELOVL5 also decreases eicosanoid levels in alveolar epithelial cells. In vivo CRISPR screen (AAV9-Sleeping Beauty), Elovl5 conditional knockout in lung epithelial cells, co-immunoprecipitation of ELOVL5 with STING, STING-TBK1 interaction assay, Golgi trafficking assay, eicosanoid profiling bioRxivpreprint Medium
2025 ELOVL5 promotes VLC-PUFA production in HCMV-infected cells and aids removal of erucic acid (C22:1, an endogenous antiviral fatty acid) by elongation; ELOVL5 activity is stimulated by HCMV infection and reduces C22:1 levels, thereby mollifying the antiviral effect of erucic acid on virus replication. Lipidomics, erucic acid supplementation, ELOVL5 functional assay in HCMV-infected cells bioRxivpreprint Low
2025 ELOVL5 is a super-enhancer-driven oncogene in T-ALL; ELOVL5 knockdown suppresses T-ALL cell proliferation and induces apoptosis in vitro and reduces tumor burden in xenograft models; RNA-seq shows ELOVL5 promotes T-ALL progression by activating MYC signaling and upregulating SERBP1. H3K27ac ChIP-seq, shRNA knockdown, RNA-seq, xenograft mouse models, SERBP1 silencing Genomics Medium 41016515

Source papers

Stage 0 corpus · 69 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2008 Deletion of ELOVL5 leads to fatty liver through activation of SREBP-1c in mice. Journal of lipid research 186 18838740
2009 Highly unsaturated fatty acid synthesis in Atlantic salmon: characterization of ELOVL5- and ELOVL2-like elongases. Marine biotechnology (New York, N.Y.) 146 19184219
2010 Genome-wide association study of normal tension glaucoma: common variants in SRBD1 and ELOVL5 contribute to disease susceptibility. Ophthalmology 93 20363506
2014 ELOVL5 mutations cause spinocerebellar ataxia 38. American journal of human genetics 82 25065913
2021 ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer. Cancer research 76 33547161
2014 Supplementation with N-3 long-chain polyunsaturated fatty acids or olive oil in men and women with renal disease induces differential changes in the DNA methylation of FADS2 and ELOVL5 in peripheral blood mononuclear cells. PloS one 70 25329159
2014 The capacity for long-chain polyunsaturated fatty acid synthesis in a carnivorous vertebrate: Functional characterisation and nutritional regulation of a Fads2 fatty acyl desaturase with Δ4 activity and an Elovl5 elongase in striped snakehead (Channa striata). Biochimica et biophysica acta 50 25542509
2012 Elovl5 regulates the mTORC2-Akt-FOXO1 pathway by controlling hepatic cis-vaccenic acid synthesis in diet-induced obese mice. Journal of lipid research 49 23099444
2014 Fatty acid elongase-5 (Elovl5) regulates hepatic triglyceride catabolism in obese C57BL/6J mice. Journal of lipid research 46 24814977
2013 Molecular basis for differential elongation of omega-3 docosapentaenoic acid by the rat Elovl5 and Elovl2. Journal of lipid research 46 23873268
2015 Polyunsaturated fatty acid metabolism in a marine teleost, Nibe croaker Nibea mitsukurii: Functional characterization of Fads2 desaturase and Elovl5 and Elovl4 elongases. Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology 43 26112824
2011 Association between SRBD1 and ELOVL5 gene polymorphisms and primary open-angle glaucoma. Investigative ophthalmology & visual science 37 21508110
2013 An evolutionary perspective on Elovl5 fatty acid elongase: comparison of Northern pike and duplicated paralogs from Atlantic salmon. BMC evolutionary biology 34 23597093
2017 Motor Deficits and Cerebellar Atrophy in Elovl5 Knock Out Mice. Frontiers in cellular neuroscience 29 29163054
2022 Downregulation of Elovl5 promotes breast cancer metastasis through a lipid-droplet accumulation-mediated induction of TGF-β receptors. Cell death & disease 28 36056008
2017 Estrogen Promotes Hepatic Synthesis of Long-Chain Polyunsaturated Fatty Acids by Regulating ELOVL5 at Post-Transcriptional Level in Laying Hens. International journal of molecular sciences 28 28665359
2016 Clinical and neuroradiological features of spinocerebellar ataxia 38 (SCA38). Parkinsonism & related disorders 28 27143115
2018 Polyunsaturated fatty acid elongation and desaturation in activated human T-cells: ELOVL5 is the key elongase. Journal of lipid research 27 30293059
2020 Polyunsaturated fatty acids synthesized by freshwater fish: A new insight to the roles of elovl2 and elovl5 in vivo. Biochemical and biophysical research communications 26 32883522
2022 ELOVL5-mediated fatty acid elongation promotes cellular proliferation and invasion in renal cell carcinoma. Cancer science 24 35670054
2015 Identification of human ELOVL5 enhancer regions controlled by SREBP. Biochemical and biophysical research communications 22 26321664
2020 Elovl2 But Not Elovl5 Is Essential for the Biosynthesis of Docosahexaenoic Acid (DHA) in Zebrafish: Insight from a Comparative Gene Knockout Study. Marine biotechnology (New York, N.Y.) 21 32880080
2014 Functional characterization of the duck and turkey fatty acyl elongase enzymes ELOVL5 and ELOVL2. The Journal of nutrition 21 24919687
2021 ELOVL5-Mediated Long Chain Fatty Acid Elongation Contributes to Enzalutamide Resistance of Prostate Cancer. Cancers 20 34439125
2023 ELOVL5 and IGFBP6 genes modulate sensitivity of breast cancer cells to ferroptosis. Frontiers in molecular biosciences 18 36714261
2019 Long-term efficacy of docosahexaenoic acid (DHA) for Spinocerebellar Ataxia 38 (SCA38) treatment: An open label extension study. Parkinsonism & related disorders 18 30862453
2019 DHA intake interacts with ELOVL2 and ELOVL5 genetic variants to influence polyunsaturated fatty acids in human milk. Journal of lipid research 18 30914501
2019 Effect of gestational oily fish intake on the risk of allergy in children may be influenced by FADS1/2, ELOVL5 expression and DNA methylation. Genes & nutrition 18 31244960
2019 miR-21-3p Targets Elovl5 and Regulates Triglyceride Production in Mammary Epithelial Cells of Cow. DNA and cell biology 17 30707627
2018 Genome-wide methylation analysis identifies ELOVL5 as an epigenetic biomarker for the risk of type 2 diabetes mellitus. Scientific reports 17 30291282
2005 Mutation screening of three candidate genes, ELOVL5, SMAP1 and GLULD1 in autosomal recessive retinitis pigmentosa. International journal of molecular medicine 17 16273301
2021 Effect of the Expression of ELOVL5 and IGFBP6 Genes on the Metastatic Potential of Breast Cancer Cells. Frontiers in genetics 15 34149804
2021 Ovine ELOVL5 and FASN genes polymorphisms and their correlations with sheep tail fat deposition. Gene 15 34500050
2018 Fatty acid elongase 5 (ELOVL5) alters the synthesis of long-chain unsaturated fatty acids in goat mammary epithelial cells. Journal of dairy science 15 29454701
2012 The SNP in the promoter region of the bovine ELOVL5 gene influences economic traits including subcutaneous fat thickness. Molecular biology reports 15 23269620
2018 Cloning, tissue distribution, functional characterization and nutritional regulation of a fatty acyl Elovl5 elongase in chu's croaker Nibea coibor. Gene 14 29555199
2018 miR-146a is involved in the regulation of vertebrate LC-PUFA biosynthesis by targeting elovl5 as demonstrated in rabbitfish Siganus canaliculatus. Gene 14 30145362
2017 Cloning and functional characterization of fads2 desaturase and elovl5 elongase from Japanese flounder Paralichthys olivaceus. Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology 13 28943298
2016 Cloning, expression and functional characterization of the polyunsaturated fatty acid elongase (ELOVL5) gene from sea cucumber (Apostichopus japonicus). Gene 13 27538705
2023 miR-19b-3p regulated by estrogen controls lipid synthesis through targeting MSMO1 and ELOVL5 in LMH cells. Poultry science 12 37939591
2018 The Transcriptional Factor PPARαb Positively Regulates Elovl5 Elongase in Golden Pompano Trachinotus ovatus (Linnaeus 1758). Frontiers in physiology 12 30319448
2017 Methylation associated transcriptional repression of ELOVL5 in novel colorectal cancer cell lines. PloS one 12 28931069
2016 Molecular Cloning, Functional Characterization and Nutritional Regulation of the Putative Elongase Elovl5 in the Orange-Spotted Grouper (Epinephelus coioides). PloS one 12 26950699
2022 Environmental adaptation in fish induced changes in the regulatory region of fatty acid elongase gene, elovl5, involved in long-chain polyunsaturated fatty acid biosynthesis. International journal of biological macromolecules 11 35120941
2016 Dietary Oil Source and Selenium Supplementation Modulate Fads2 and Elovl5 Transcriptional Levels in Liver and Brain of Meagre (Argyrosomus regius). Lipids 11 27169705
2022 Glioblastoma Multiforme Tumors in Women Have a Lower Expression of Fatty Acid Elongases ELOVL2, ELOVL5, ELOVL6, and ELOVL7 than in Men. Brain sciences 9 36291290
2007 Localization of the candidate genes ELOVL5 and SCD1 for 'male effect' pheromone synthesis in goats (Capra hircus). The Journal of reproduction and development 9 17827874
2023 Spinocerebellar ataxia 38: structure-function analysis shows ELOVL5 G230V is proteotoxic, conformationally altered and a mutational hotspot. Human genetics 8 37199746
2021 ELOVL5 Participates in Embryonic Lipid Determination of Cellular Membranes and Cytoplasmic Droplets. International journal of molecular sciences 8 33525659
2016 Regulatory divergence of homeologous Atlantic salmon elovl5 genes following the salmonid-specific whole-genome duplication. Gene 8 27374149
2021 Elovl5 Expression in the Central Nervous System of the Adult Mouse. Frontiers in neuroanatomy 7 33994961
2020 Functional characterisation of fatty acyl desaturase, Fads2, and elongase, Elovl5, in the Boddart's goggle-eyed goby Boleophthalmus boddarti (Gobiidae) suggests an incapacity for long-chain polyunsaturated fatty acid biosynthesis. Journal of fish biology 7 32222967
2020 Seawater Culture Increases Omega-3 Long-Chain Polyunsaturated Fatty Acids (N-3 LC-PUFA) Levels in Japanese Sea Bass (Lateolabrax japonicus), Probably by Upregulating Elovl5. Animals : an open access journal from MDPI 7 32957627
2017 Genetic Variants in the ELOVL5 but not ELOVL2 Gene Associated with Polyunsaturated Fatty Acids in Han Chinese Breast Milk. Biomedical and environmental sciences : BES 7 28245901
2017 Molecular characterization, tissue distribution and differential nutritional regulation of putative Elovl5 elongase in silver barb (Puntius gonionotus). Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology 5 29233754
2024 ELOVL5 and VLDLR synergistically affect n-3 PUFA deposition in eggs of different chicken breeds. Poultry science 4 39018654
2022 Effects of the administration of Elovl5-dependent fatty acids on a spino-cerebellar ataxia 38 mouse model. Behavioral and brain functions : BBF 4 35933444
2020 The requirements for sterol regulatory element-binding protein (Srebp) and stimulatory protein 1 (Sp1)-binding elements in the transcriptional activation of two freshwater fish Channa striata and Danio rerio elovl5 elongase. Fish physiology and biochemistry 4 32239337
2015 [Two Elovl5-like elongase genes in Cyprinus carpio var. Jian: Gene characterization, mRNA expression, and nutritional regulation]. Molekuliarnaia biologiia 4 26299859
2024 miR-218-5p promotes hepatic lipogenesis through targeting Elovl5 in non-alcoholic fatty liver disease. Biochemical pharmacology 3 38972428
2023 Hepatic transcriptome analysis reveals that elovl5 deletion promotes PUFA biosynthesis and deposition. Comparative biochemistry and physiology. Part D, Genomics & proteomics 3 37080058
2015 Single nucleotide polymorphisms of Δ6-desaturase and Elovl5 segments and their associations with common carp (Cyprinus carpio) growth traits. Genetics and molecular research : GMR 3 26505436
2023 Deletion of Elovl5 leads to dyslipidemia and atherosclerosis in LDLR-deficient mice. Biochemical and biophysical research communications 2 38000296
2019 Immunolocalization of c-Fos, ELOVL5 and oestradiol in the ewe vulva in relation to oestrus behaviour after treatment with lipopolysaccharide. Reproduction in domestic animals = Zuchthygiene 2 31765035
2015 SCA38 is rare in Mainland China. Journal of the neurological sciences 1 26433464
2025 Impact of Elovl5 Deficiency on Cerebellar Excitatory Synaptic Transmission in Mice. The Journal of neuroscience : the official journal of the Society for Neuroscience 0 40789653
2025 Super-enhancer-driven ELOVL5 promotes T-ALL progression through the MYC-SERBP1 pathway. Genomics 0 41016515
2025 ELOVL5 Regulates Ferroptosis in Breast Cancer Cells. Doklady. Biochemistry and biophysics 0 41329269
2020 [Transgenesis of Drosophila melanogaster with an Elovl5 gene enables the production of longer-chain fatty acids]. Sheng wu gong cheng xue bao = Chinese journal of biotechnology 0 33169581